Disease Site Breast Disease You have free access to this content Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast (pages 39–47)
Henry M. Kuerer, Aman U. Buzdar, Elizabeth A. Mittendorf, Francisco J. Esteva, Anthony Lucci, Luis M. Vence, Laszlo Radvanyi, Funda Meric-Bernstam, Kelly K. Hunt and William Fraser Symmans
Version of Record online: 24 AUG 2010 | DOI: 10.1002/cncr.25399
Single-dose preoperative monotherapy with trastuzumab for patients with HER2-positive DCIS results in the early ability to mount antibody dependent cellular cytotoxicity mediated through natural killer cells and may also induce T-cell dependent humoral immunity.
You have free access to this content Assessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17 (pages 48–53)
Semir Vranic, Bryan Teruya, Susan Repertinger, Pamela Ulmer, Jill Hagenkord and Zoran Gatalica
Version of Record online: 27 AUG 2010 | DOI: 10.1002/cncr.25580
Increased CEP17 signals detected in invasive breast carcinomas may lead to discordant interpretation of gene amplification in a significant proportion of cases, depending on which criterion (ratio vs absolute number) is used for interpretation. However, increased gene dosage (>6
HER2 genes or HER2/CEP17 ratio >2.2), regardless of the evaluation method, is positively correlated with HER2 protein expression. You have free access to this content Effect of radiotherapy boost and hypofractionation on outcomes in ductal carcinoma in situ (pages 54–62)
Elaine S. Wai, Mary L. Lesperance, Cheryl S. Alexander, Pauline T. Truong, Matthew Culp, Patricia Moccia, Jennifer F. Lindquist and Ivo A. Olivotto
Version of Record online: 27 AUG 2010 | DOI: 10.1002/cncr.25344
Radiotherapy significantly decreased risk of local recurrence after breast-conserving surgery in patients with ductal carcinoma in situ. Additional boost radiotherapy and hypofractionation schedules did not significantly alter the effect of the radiotherapy.
Gastrointestinal Disease You have free access to this content Endoscopic esophageal tumor length : A prognostic factor for patients with esophageal cancer (pages 63–69)
Puja Gaur, Boris Sepesi, Wayne L. Hofstetter, Arlene M. Correa, Manoop S. Bhutani, Thomas J. Watson, Stephen G. Swisher and Members of the M. D. Anderson Esophageal Cancer Group and the University of Rochester School of Medicine and Dentistry Foregut Group
Version of Record online: 27 AUG 2010 | DOI: 10.1002/cncr.25373
In this study, endoscopically measured tumor length was identified as an independent predictor of survival for patients with esophageal adenocarcinoma. The results indicated that this measure may be used to identify high-risk patients who may benefit from neoadjuvant therapy before they undergo surgical resection.
You have free access to this content Expanding colorectal cancer screening among minority women (pages 70–76)
Moshe Shike, Mark Schattner, Alvaro Genao, Winsome Grant, Margaret Burke, Ann Zauber, Lianne Russo and Valerie Cuyjet
Version of Record online: 25 OCT 2010 | DOI: 10.1002/cncr.25566
Offering colorectal cancer screening to poor minority women at the time of mammography is an effective way to expand screening in this otherwise underserved population. Screening colonoscopy findings in this population were similar to those in the general population. Alternatives to traditional medical insurance are needed for the uninsured.
You have free access to this content Phase 1 clinical trials in 83 patients with pancreatic cancer : The M. D. Anderson Cancer Center experience (pages 77–85)
Christos Vaklavas, Apostolia-Maria Tsimberidou, Sijin Wen, David Hong, Jennifer Wheler, Chaan S. Ng, Aung Naing, Cynthia Uehara, Robert A. Wolff and Razelle Kurzrock
Version of Record online: 24 AUG 2010 | DOI: 10.1002/cncr.25346
Of 83 patients with pancreatic cancer treated in the phase 1 program, the median survival duration from presentation in the phase 1 clinic was 5.0 months (95% confidence interval, 3.3-6.2), which compared favorably to the survival duration observed with best supportive care (3 months). The results suggest that phase 1 clinical trials offer a reasonable therapeutic approach for patients with advanced pancreatic cancer.
You have free access to this content Putative tumor suppressor miR-145 inhibits colon cancer cell growth by targeting oncogene friend leukemia virus integration 1 gene (pages 86–95)
Jianjun Zhang, Haiyan Guo, He Zhang, Haibo Wang, Guanxiang Qian, Xianqun Fan, Andrew R. Hoffman, Ji-Fan Hu and Shengfang Ge
Version of Record online: 24 AUG 2010 | DOI: 10.1002/cncr.25522
The authors identified
FLI1, a gene involved in t(11;22)(q24:q12) reciprocal chromosomal translocation in Ewing sarcoma, as a novel target of miR-145, suggesting that miR-145 functions as a tumor suppressor by down-regulating oncogenic FLI1 in colon cancer. Genitourinary Disease You have free access to this content Effects of complementary therapies on clinical outcomes in patients being treated with radiation therapy for prostate cancer (pages 96–102)
Clair Beard, William B. Stason, Qian Wang, Judith Manola, Elizabeth Dean-Clower, Jeffery A. Dusek, Susan DeCristofaro, Ann Webster, Anne M. Doherty-Gilman, David S. Rosenthal and Herbert Benson
Version of Record online: 27 AUG 2010 | DOI: 10.1002/cncr.25291
This pilot randomized controlled trial (RCT) examined the clinical effects of 2 complementary (CAM) therapies—relaxation response therapy (RRT) and Reiki therapy—in men being treated with external beam radiotherapy (EBRx) for prostate cancer and documented the feasibility of conducting a RCT of CAM therapies in men undergoing EBRx for prostate cancer. It was found that RRT improved emotional well being and anxiety in study participants.
You have free access to this content A population-based competing-risks analysis of the survival of patients treated with radical cystectomy for bladder cancer (pages 103–109)
Giovanni Lughezzani, Maxine Sun, Shahrokh F. Shariat, Lars Budäus, Rodolphe Thuret, Claudio Jeldres, Daniel Liberman, Francesco Montorsi, Paul Perrotte and Pierre I. Karakiewicz
Version of Record online: 27 AUG 2010 | DOI: 10.1002/cncr.25345
A valuable graphical aid was developed for prediction of cancer-specific and other-cause mortality according to disease stage and patient age. It can help clinicians better stratify the risk-benefit ratio of radical cystectomy.
Hematologic Malignancies You have free access to this content Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy (pages 110–115)
Farshid Dayyani, Hagop Kantarjian, Susan O'Brien, Sherry Pierce, Dan Jones, Stefan Faderl, Guillermo Garcia-Manero, Jorge Cortes and Farhad Ravandi
Version of Record online: 27 AUG 2010 | DOI: 10.1002/cncr.25585
To the best of the authors' knowledge, outcomes of patients with therapy-related acute promyelocytic leukemia (t-APL) who were treated with arsenic trioxide (ATO) as frontline regimens are not known. In the current study, survival rates for patients with t-APL who were treated with all-
trans-retinoic acid (ATRA) plus ATO were compared with those for patients who received a chemotherapy-based induction regimen and found to be similar. You have free access to this content Self-administered, subcutaneous alemtuzumab to treat residual disease in patients with chronic lymphocytic leukemia (pages 116–124)
William G. Wierda, Thomas J. Kipps, Michael J. Keating, Jennifer R. Brown, John G. Gribben, Mary Browning, Laura Z. Rassenti, Andrew W. Greaves, Donna Neuberg, Susan M. O'Brien and and the CLL Research Consortium
Version of Record online: 30 AUG 2010 | DOI: 10.1002/cncr.25379
The results from this study demonstrated that self-administered, subcutaneous alemtuzumab was safe and active for residual disease and that plasma alemtuzumab levels and real-time minimal residual disease evaluation are important endpoints to monitor in alemtuzumab consolidation trials.
Hepatobiliary Disease You have free access to this content Pegylated liposomal doxorubicin and gemcitabine in patients with advanced hepatocellular carcinoma : Results of a phase 2 study (pages 125–133)
Giuseppe Lombardi, Fable Zustovich, Fabio Farinati, Umberto Cillo, Alessandro Vitale, Giacomo Zanus, Martin Donach, Miriam Farina, Stefania Zovato and Davide Pastorelli
Version of Record online: 31 AUG 2010 | DOI: 10.1002/cncr.25578
The authors tested the combination of gemcitabine plus pegylated liposomal doxorubicin in patients with advanced hepatocellular carcinoma. This combination was demonstrated to be active and safe.
Lung Disease You have free access to this content Quality of surgical resection for nonsmall cell lung cancer in a US metropolitan area (pages 134–142)
Jeffrey W. Allen, Aamer Farooq, Thomas F. O'Brien and Raymond U. Osarogiagbon
Version of Record online: 24 AUG 2010 | DOI: 10.1002/cncr.25334
The degree of compliance with quality measures as outlined by national leadership groups in surgical resection of non-small cell lung cancer patients is poor. We evaluated a consecutive series of NSCLC resections in a large metropolitan US city and compared the surgical procedures to three national guidelines. Interventions aimed at increasing the degree of lymph node sampling are needed.
You have free access to this content Clinical impact of amphiregulin expression in patients with epidermal growth factor receptor (EGFR) wild-type nonsmall cell lung cancer treated with EGFR-tyrosine kinase inhibitors (pages 143–151)
Myung Hee Chang, Hee Kyung Ahn, Jeeyun Lee, Chan-Kwon Jung, Yoon-La Choi, Yeon Hee Park, Jin Seok Ahn, Keunchil Park and Myung-Ju Ahn
Version of Record online: 27 AUG 2010 | DOI: 10.1002/cncr.25560
Patients with wild-type epidermal growth factor receptor (WT EGFR)-positive nonsmall cell lung cancer (NSCLC) may benefit clinically from treatment with EGFR tyrosine kinase inhibitors (TKIs) through the regulation of amphiregulin expression. The results suggested that amphiregulin expression may be another potential marker for the selection of EGFR-TKI treatment in patients with WT EGFR-positive NSCLC.
Melanoma You have free access to this content The expanding melanoma burden in California hispanics : Importance of socioeconomic distribution, histologic subtype, and anatomic location (pages 152–161)
Ricardo A. Pollitt, Christina A. Clarke, Susan M. Swetter, David H. Peng, John Zadnick and Myles Cockburn
Version of Record online: 24 AUG 2010 | DOI: 10.1002/cncr.25355
The socioeconomic distribution of melanoma incidence and tumor thickness differed starkly between Hispanic and non-Hispanic white Californians, particularly among men. Melanoma prevention efforts targeted to Hispanics of lower socioeconomic status and increased physician awareness of melanoma patterns among Hispanics are needed.
Neuro-Oncology You have free access to this content Expression of the stem cell marker CD133 in recurrent glioblastoma and its value for prognosis (pages 162–174)
Roberto Pallini, Lucia Ricci-Vitiani, Nicola Montano, Cristiana Mollinari, Mauro Biffoni, Tonia Cenci, Francesco Pierconti, Maurizio Martini, Ruggero De Maria and Luigi Maria Larocca
Version of Record online: 30 AUG 2010 | DOI: 10.1002/cncr.25581
In glioblastoma that recurred after radiochemotherapy, the fraction of CD133-positive cells increased by 4.6-fold compared with paired tumors at first diagnosis; however, increased CD133 expression was associated significantly with longer survival. By using chromosomal analysis and in vivo xenografts, the authors of this report demonstrated that the CD133-positive cell compartment of recurrent glioblastoma is composed of cancer stem cells and nontumor neural stem cells and that the relative amount of the latter cells favorably affects patient survival.
Sarcoma You have free access to this content Clinical outcomes for patients with soft tissue sarcoma of the hand (pages 175–179)
Mark E. Puhaindran, Rachel S. Rohde, Joanne Chou, Carol D. Morris and Edward A. Athanasian
Version of Record online: 31 AUG 2010 | DOI: 10.1002/cncr.25593
This study assessed clinical outcomes for patients with soft tissue sarcoma of the hand. The results suggested that aggressive surgical treatment can result in better clinical outcomes, and underscored that care must be taken when planning biopsies of hand tumors.
Discipline Disparities Research You have free access to this content The association of race/ethnicity, insurance status, and socioeconomic factors with breast cancer care (pages 180–189)
Rachel A. Freedman, Katherine S. Virgo, Yulei He, Alexandre L. Pavluck, Eric P. Winer, Elizabeth M. Ward and Nancy L. Keating
Version of Record online: 11 OCT 2010 | DOI: 10.1002/cncr.25542
The authors observed that black women had modestly lower rates of guideline-recommended breast cancer care compared with white women. The lower rates in receipt of care were insensitive to adjustment for insurance and area-level socioeconomic status.
Outcomes Research You have free access to this content Cognitive impairment in men with testicular cancer prior to adjuvant therapy (pages 190–196)
Jeffrey S. Wefel, Damon J. Vidrine, Tracy L. Veramonti, Christina A. Meyers, Salma K. Marani, Harald J. Hoekstra, Josette E. H. M. Hoekstra-Weebers, Lokesh Shahani and Ellen R. Gritz
Version of Record online: 24 AUG 2010 | DOI: 10.1002/cncr.25298
A significant number of men with NSGCT exhibited cognitive impairment before chemotherapy. The domains of cognitive function most frequently affected include verbal learning, executive function, and fine motor dexterity.
Pediatric Oncology You have free access to this content Prognostic factors and long-term outcomes of childhood nasopharyngeal carcinoma (pages 197–206)
Daniel Ka Leung Cheuk, Catherine A. Billups, Michael G. Martin, Cynthia R. Roland, Raul C. Ribeiro, Matthew J. Krasin and Carlos Rodriguez-Galindo
Version of Record online: 24 AUG 2010 | DOI: 10.1002/cncr.25376
The authors evaluated the long-term outcomes of childhood nasopharyngeal carcinoma. Although survival rates improved over the past 4 decades with cisplatin-based chemotherapy and higher radiotherapy doses, many survivors had long-term treatment-related morbidities.
You have free access to this content Elevated expression of CXC chemokines in pediatric osteosarcoma patients (pages 207–217)
Yiting Li, Ricardo Flores, Alexander Yu, M. Fatih Okcu, Jeffrey Murray, Murali Chintagumpala, John Hicks, Ching C. Lau and Tsz-Kwong Man
Version of Record online: 30 AUG 2010 | DOI: 10.1002/cncr.25563
Two CXC chemokines, CXCL4 and CXCL6, were higher in the plasma of osteosarcoma patients and frequently expressed in the tumor. Results showed that these 2 chemokines could be useful for prognostication of osteosarcoma, and targeting these chemokines and their receptors may also provide therapeutic potential.
Psychosocial Oncology You have free access to this content Screening for major depression in cancer outpatients : The diagnostic accuracy of the 9-item patient health questionnaire (pages 218–227)
Parvez Thekkumpurath, Jane Walker, Isabella Butcher, Laura Hodges, Annet Kleiboer, Mark O'Connor, Lucy Wall, Gordon Murray, Kurt Kroenke and Michael Sharpe
Version of Record online: 24 AUG 2010 | DOI: 10.1002/cncr.25514
When the 9-item Patient Health Questionnaire (PHQ-9) was scored as a continuous measure with a cutoff score ≥8, it performed well in identifying major depressive disorder among cancer patients. The current findings indicated that the PHQ-9 should be considered as a screening instrument in this population.